Compounds > 1-oleoyl-2-palmitoylphosphatidylcholine

1-oleoyl-2-palmitoylphosphatidylcholine and Cardiovascular-Diseases

1-oleoyl-2-palmitoylphosphatidylcholine has been researched along with Cardiovascular-Diseases* in 1 studies

Reviews

1 review(s) available for 1-oleoyl-2-palmitoylphosphatidylcholine and Cardiovascular-Diseases

Article	Year
ETC-588 (Pfizer). Current opinion in investigational drugs (London, England : 2000), 2004, Volume: 5, Issue:9 Pfizer, following its acquisition of Esperion Therapeutics in the first quarter of 2004, is developing ETC-588 as a potential acute treatment for ischemia caused by atherosclerosis. Enrollment in phase II trials in patients with acute coronary syndrome is complete. Topics: Animals; Cardiovascular Agents; Cardiovascular Diseases; Humans; Phosphatidylcholines; Randomized Controlled Trials as Topic	2004

Article

Year

Current opinion in investigational drugs (London, England : 2000), 2004, Volume: 5, Issue:9

Pfizer, following its acquisition of Esperion Therapeutics in the first quarter of 2004, is developing ETC-588 as a potential acute treatment for ischemia caused by atherosclerosis. Enrollment in phase II trials in patients with acute coronary syndrome is complete.

Topics: Animals; Cardiovascular Agents; Cardiovascular Diseases; Humans; Phosphatidylcholines; Randomized Controlled Trials as Topic

2004